eTheRNA immunotherapies NV (‘eTheRNA’), an mRNA technology discovery and development company with a full platform of integrated capabilities, today announced that it will host a key opinion leader (KOL) webinar on mRNA-lipid nanoparticles (LNP) for cancer immunotherapy on Wednesday, March 2, 2022 at 10am ET / 3pm GMT / 4pm CET.
NIEL, Belgium, Feb. 28, 2022 (GLOBE NEWSWIRE) -- eTheRNA Immunotherapies NV (‘eTheRNA’), an mRNA technology discovery and development company with a full platform of integrated capabilities, today announced that it will host a key opinion leader (KOL) webinar on mRNA-lipid nanoparticles (LNP) for cancer immunotherapy on Wednesday, March 2, 2022 at 10am ET / 3pm GMT / 4pm CET.
eTheRNA’s VP of Discovery Stefaan De Koker, Ph.D., will provide an overview of eTheRNA’s LNP technology developed for its cancer immunotherapy programs.
This will be followed by a Q&A discussion with Principal Investigator Michael J. Mitchell, Ph.D., Professor in the Department of Bioengineering at the University of Pennsylvania. The Mitchell Lab performs research that lies at the interface of biomaterials science, drug delivery, and cellular and molecular bioengineering to fundamentally understand and therapeutically target biological barriers. Currently, their research focuses on the synthesis of novel biomaterials and nanoparticles for the delivery of nucleic acids (siRNA, miRNA, mRNA, CRISPR-Cas9).
The session will conclude with Q&A open to the attendees.
To register for the event, please click here.
About eTheRNA immunotherapies
eTheRNA is an mRNA technology discovery and development company with a full platform of integrated capabilities including: mRNA construct design and optimization; proprietary lipid nanoparticle (LNP) formulations which have demonstrated organ-specific distribution preclinically; process development and manufacturing capabilities for mRNA drug substance (gram GMP scale); and proprietary LNP / final product formulation technologies, including a lyophilized thermostable formulation in advanced development. With a focus on immune modulation and T Cell stimulation, eTheRNA is pursuing internal development programs to validate its core technologies and enable strategic partnerships in a range of geographic markets and therapeutic areas. eTheRNA is backed by a global syndicate of leading investors and is headquartered in Belgium with offices in New York and Hong Kong. To learn more, visit www.etherna.be.
For more information, please contact:
Johanna Madero
eTheRNA immunotherapies
media@etherna.be
